These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 27758856

  • 1. Novel Antibody for the Treatment of Transthyretin Amyloidosis.
    Hosoi A, Su Y, Torikai M, Jono H, Ishikawa D, Soejima K, Higuchi H, Guo J, Ueda M, Suenaga G, Motokawa H, Ikeda T, Senju S, Nakashima T, Ando Y.
    J Biol Chem; 2016 Nov 25; 291(48):25096-25105. PubMed ID: 27758856
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
    Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, Yamashita T, Oshima T, Nakamura T, Ikemizu S, Anan I, Suhr O, Ando Y.
    Clin Chim Acta; 2013 Apr 18; 419():127-31. PubMed ID: 23462670
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clusterin regulates transthyretin amyloidosis.
    Lee KW, Lee DH, Son H, Kim YS, Park JY, Roh GS, Kim HJ, Kang SS, Cho GJ, Choi WS.
    Biochem Biophys Res Commun; 2009 Oct 16; 388(2):256-60. PubMed ID: 19664600
    [Abstract] [Full Text] [Related]

  • 8. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis.
    Köppen J, Kleinschmidt M, Morawski M, Rahfeld JU, Wermann M, Cynis H, Hegenbart U, Daniel C, Roßner S, Schilling S, Schulze A.
    Amyloid; 2024 Sep 16; 31(3):184-194. PubMed ID: 38801321
    [Abstract] [Full Text] [Related]

  • 9. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy.
    Palha JA, Moreira P, Olofsson A, Lundgren E, Saraiva MJ.
    J Mol Med (Berl); 2001 Sep 16; 78(12):703-7. PubMed ID: 11434723
    [Abstract] [Full Text] [Related]

  • 10. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
    Ferreira N, Saraiva MJ, Almeida MR.
    PLoS One; 2012 Sep 16; 7(1):e29933. PubMed ID: 22253829
    [Abstract] [Full Text] [Related]

  • 11. [Pathogenesis and therapy for transthyretin related amyloidosis].
    Ando Y, Jono H.
    Rinsho Byori; 2008 Feb 16; 56(2):114-20. PubMed ID: 18402051
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models.
    Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ.
    J Transl Med; 2010 Jul 30; 8():74. PubMed ID: 20673327
    [Abstract] [Full Text] [Related]

  • 14. Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy.
    Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y, Mizuguchi M, Ueda M, Shinriki S, Shono M, Obayashi K, Arima H, Ando Y.
    Amyloid; 2012 Jun 30; 19 Suppl 1():50-2. PubMed ID: 22620966
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic Potential of Polyamidoamine Dendrimer for Amyloidogenic Transthyretin Amyloidosis.
    Inoue M, Ueda M, Higashi T, Anno T, Fujisawa K, Motoyama K, Mizuguchi M, Ando Y, Jono H, Arima H.
    ACS Chem Neurosci; 2019 May 15; 10(5):2584-2590. PubMed ID: 30912637
    [Abstract] [Full Text] [Related]

  • 16. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
    Berg I, Thor S, Hammarström P.
    Neurodegener Dis; 2009 May 15; 6(3):127-38. PubMed ID: 19372706
    [Abstract] [Full Text] [Related]

  • 17. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.
    Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y.
    Clin Chem; 2009 Jun 15; 55(6):1223-7. PubMed ID: 19372189
    [Abstract] [Full Text] [Related]

  • 18. Presence of autoantibody against ATTR Val30Met after sequential liver transplantation.
    Ando Y, Terazaki H, Haraoka K, Tajiri T, Nakamura M, Obayashi K, Misumi S, Shoji S, Hata K, Nakagawa K, Ishizaki T, Uemoto S, Inomata Y, Tanaka K, Okabe H.
    Transplantation; 2002 Mar 15; 73(5):751-5. PubMed ID: 11907422
    [Abstract] [Full Text] [Related]

  • 19. Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy.
    Kugimiya T, Jono H, Saito S, Maruyama T, Kadowaki D, Misumi Y, Hoshii Y, Tasaki M, Su Y, Ueda M, Obayashi K, Shono M, Otagiri M, Ando Y.
    Lab Invest; 2011 Aug 15; 91(8):1219-28. PubMed ID: 21537325
    [Abstract] [Full Text] [Related]

  • 20. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
    Hayashi Y, Jono H.
    Biol Pharm Bull; 2018 Aug 15; 41(12):1737-1744. PubMed ID: 30504675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.